Success of Radiofrequency Catheter Ablation of Atrial Fibrillation: Does Obesity Influence the Outcomes?

Dhanunjaya R Lakkireddy1, George E Blake1, Dimpi Patel2

  • 1Mid America Cardiology @ University of Kansas Hospital, Kansas City, KS.

Insights

Obesity significantly increases the risk of atrial fibrillation (AF) recurrence after catheter ablation. Higher body mass index (BMI) correlates with greater AF relapse rates, impacting long-term treatment success.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Obesity Medicine

Background:

  • Catheter ablation is a common treatment for symptomatic atrial fibrillation (AF) refractory to antiarrhythmic drugs.
  • Higher body mass index (BMI) is linked to poorer outcomes in cardiovascular interventions, but its specific impact on AF ablation success is unclear.

Purpose of the Study:

  • To investigate the association between body mass index (BMI) and the success rate of catheter ablation for atrial fibrillation (AF).

Main Methods:

  • A prospective study of 511 patients undergoing AF ablation between 2002-2005.
  • Patients were stratified into four BMI classes (I to IV).
  • AF recurrence after 3 months, confirmed by follow-up for at least 12 months, defined ablation failure.

Main Results:

  • Higher BMI classes (III and IV) showed increased prevalence of male sex, diabetes, smoking, coronary artery disease, left atrial enlargement, and longstanding AF.
  • Obesity, measured by BMI, demonstrated a direct correlation with both early (p=0.05) and late (p=0.01) AF recurrence post-ablation.

Conclusions:

  • Obesity is a significant predictor of long-term atrial fibrillation recurrence following catheter ablation.
  • Factors such as smoking and left atrial enlargement may contribute to higher failure rates in obese patient subgroups.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
326
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
261
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
316